FDA reprimands Lundbeck Seattle Biopharmaceuticals for inflated claims on Vyepti migraine webpages

The U.S. Food and Drug Administration issued an untitled letter to Lundbeck Seattle Biopharmaceuticals criticizing two promotional webpages about its migraine treatment Vyepti.

The agency said the pages contained claims that overstated the drug’s efficacy, which the FDA considers misleading to patients and healthcare providers.

Following the FDA’s concerns, Lundbeck removed both webpages from its website.

The episode highlights ongoing regulatory vigilance over how migraine therapies are marketed and may prompt companies to review their digital communications.